Cargando…

Update on the second-line treatment of Helicobacter pylori infection: a narrative review

A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for Helicobacter pylori infection by the Maastricht VI/Florence Consensus Report. The m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shih, Chih-An, Shie, Chang-Bih, Tai, Wei-Chen, Chuah, Seng-Kee, Lee, Hsi-Chang, Hsu, Ping-I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Helicobacter pylori Infection – pathogenesis, management and prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478561/ https://www.ncbi.nlm.nih.gov/pubmed/37675247 http://dx.doi.org/10.1177/17562848231192750

Ejemplares similares

Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances
por: Shih, Chih-An, et al.
Publicado: (2022)

Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis
por: Chang, Yen-Lin, et al.
Publicado: (2020)

Dietary habits and Helicobacter pylori infection: is there an association?
por: Soares, Giovana Alice Sampaio, et al.
Publicado: (2023)

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention
por: Lee, Yi-Chia, et al.
Publicado: (2013)

Implications of the paradigm shift in management of Helicobacter pylori infections
por: Graham, David Y.
Publicado: (2023)

Therapeutic eradication choices in Helicobacter pylori infection in children
por: Manfredi, Marco, et al.
Publicado: (2023)

Helicobacter pylori in children: think before you kill the bug!
por: Ravikumara, M
Publicado: (2023)

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
por: Liou, Jyh-Ming, et al.
Publicado: (2016)

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
por: Oster, Paul, et al.
Publicado: (2022)

Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts
por: Wang, Song-Wei, et al.
Publicado: (2023)

A pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis
por: Zhuang, Yuan, et al.
Publicado: (2015)

Adequate amounts of probiotics increase the success rate of Helicobacter pylori eradication therapy in children
por: Kakiuchi, Toshihiko
Publicado: (2023)

Helicobacter pylori infection and micronutrient deficiency in pregnant women: a systematic review and meta-analysis
por: Afsar, Md. Nure Alam, et al.
Publicado: (2020)

A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro
por: Schlaermann, Philipp, et al.
Publicado: (2016)

Pan-genomic analyses identify key Helicobacter pylori pathogenic loci modified by carcinogenic host microenvironments
por: Noto, Jennifer M, et al.
Publicado: (2018)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Helicobacter pylori
por: Harris, A. W. (Adam W.), 1963-
Publicado: (1996)

Protein kinase C isozymes regulate matrix metalloproteinase-1 expression and cell invasion in Helicobacter pylori infection
por: Sokolova, Olga, et al.
Publicado: (2013)

CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa
por: Cook, Katherine W, et al.
Publicado: (2014)

Progressive genomic convergence of two Helicobacter pylori strains during mixed infection of a patient with chronic gastritis
por: Cao, Qizhi, et al.
Publicado: (2015)

USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis
por: Costa, Lionel, et al.
Publicado: (2020)

Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection
por: Moss, Steven F., et al.
Publicado: (2023)

Cost-effectiveness modelling of use of urea breath test for the management of Helicobacter pylori-related dyspepsia and peptic ulcer in the UK
por: Pritchard, D. Mark, et al.
Publicado: (2021)

Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7
por: Yin, Yinfei, et al.
Publicado: (2010)

Assessment of Helicobacter pylori status by examination of gastric mucosal patterns: diagnostic accuracy of white-light endoscopy and narrow-band imaging
por: Glover, Ben, et al.
Publicado: (2021)

Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention
por: Zhou, Xian-Zhu, et al.
Publicado: (2023)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
por: Suzuki, Sho, et al.
Publicado: (2020)

Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines
por: Aebischer, T, et al.
Publicado: (2008)

High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
por: Zhao, Zhe, et al.
Publicado: (2022)

High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis
por: Zhou, Ben-Gang, et al.
Publicado: (2023)

The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study
por: He, Xiao-Jian, et al.
Publicado: (2023)

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial
por: Mei, Hao, et al.
Publicado: (2022)

Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients
por: Blaecher, C, et al.
Publicado: (2013)

Review: Pathogenesis of Helicobacter pylori infection
por: Chmiela, Magdalena, et al.
Publicado: (2019)

Quinolone-Containing Therapies in the Eradication of Helicobacter pylori
por: Chuah, Seng-Kee, et al.
Publicado: (2014)

Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms
por: Sharndama, Hyelnaya Cletus, et al.
Publicado: (2022)

Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan
por: Uno, Yoshiharu
Publicado: (2019)

A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication
por: Chuah, Seng-Kee, et al.
Publicado: (2016)

The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0n8hbv69ct6fu4pgdatgmtba55